The potent, oral, pan-BCR-ABL inhibitor ponatinib has demonstrated robust antileukemic activity in a heavily pretreated population of patients with chronic myelogenous leukemia or Ph positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or nilotinib or have the T315I mutation, according to a pivotal trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.
INTENDED AUDIENCE:
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with CML/ALL
Activity Objectives:
After participating in this educational activity, participants should be better able to:
Analyze recent clinical advances in the management of Philadelphia-positive acute lymphoblastic leukemia, including second-generation tyrosine kinase inhibitors (TKIs) and multi-kinase inhibitors
Evaluate recent clinical advances in the treatment of intolerant/resistant chronic myeloid leukemia, including the use of generation TKIs
